#hematopoietic — Friday, May 01, 2026 (1 items)
| 0 | ℹ |
CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.
(nature.com)
|
Nature Medicine 2026-05-01 | #immunotherapy #crispr #genome editing #aml #hematopoietic |